Video

Dr. Min Dong discusses next steps with therapeutic toxins for urologic disease

Author(s):

Urology Times staff

“We are not just changing toxins for the sake of changing toxins; we are changing toxins to satisfy the needs from the clinical community,” says Min Dong, MD.

In this video, Min Dong, MD,summarizes the main points of his talk, “New frontiers in therapeutic toxins for urologic disease,” which was presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2022 Winter Meeting. Dong is an associate professor of Urology at Harvard Medical School in Cambridge, Massachusetts.

Related Videos
Karyn S. Eilber, MD, answers a question during a Zoom video interview
Woman at doctor | Image Credit: © rocketclips - stock.adobe.com
Closeup of patient with prescription | Image Credit: © gpointstudio - stock.adobe.com
Colin Goudelocke, MD, answers a question during a Zoom video interview
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Colin Goudelocke, MD, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Related Content
First patient enrolled in trial of Voro Urologic Scaffold for post-prostatectomy SUI
April 24th 2025

First patient enrolled in trial of Voro Urologic Scaffold for post-prostatectomy SUI

Hannah Clarke
"What is truly exciting is the potential for this device to meaningfully improve early and long-term continence rates, which can profoundly impact a patient's recovery and overall quality of life,” says Patrick Daily, MD.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Gene therapy shows encouraging efficacy for overactive bladder
April 8th 2025

Gene therapy shows encouraging efficacy for overactive bladder

Hannah Clarke
At week 12, patients in the URO-902 cohorts demonstrated significantly greater improvements in daily microuritions vs placebo.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
FDA grants 510(k) clearance to Glean Urodynamics System
April 2nd 2025

FDA grants 510(k) clearance to Glean Urodynamics System

Hannah Clarke
"Glean will enable patients to void naturally, without catheters in place. I believe this advance will yield a better test that mimics actual symptoms," says Bilal I. Chughtai, MD.
Trial launches of gene therapy vector for neurogenic bladder due to spinal cord injury
March 14th 2025

Trial launches of gene therapy vector for neurogenic bladder due to spinal cord injury

Hannah Clarke
The 52-week study plans to enroll 16 patients across 4 sites in the US.
© 2025 MJH Life Sciences

All rights reserved.